155 related articles for article (PubMed ID: 19032227)
1. Income-related disparities in kidney transplant graft failures are eliminated by Medicare's immunosuppression coverage.
Woodward RS; Page TF; Soares R; Schnitzler MA; Lentine KL; Brennan DC
Am J Transplant; 2008 Dec; 8(12):2636-46. PubMed ID: 19032227
[TBL] [Abstract][Full Text] [Related]
2. Effect of extended coverage of immunosuppressive medications by medicare on the survival of cadaveric renal transplants.
Woodward RS; Schnitzler MA; Lowell JA; Spitznagel EL; Brennan DC
Am J Transplant; 2001 May; 1(1):69-73. PubMed ID: 12095042
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Medicare's lifetime immunosuppression coverage on racial disparities in kidney graft survival.
Page TF; Woodward RS; Brennan DC
Am J Transplant; 2012 Jun; 12(6):1519-27. PubMed ID: 22335186
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Medicare's coverage of immunosuppression medications for kidney transplant recipients.
Page TF; Woodward RS
Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):435-44. PubMed ID: 19817527
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of extending Medicare coverage of immunosuppressive medications to the life of a kidney transplant.
Yen EF; Hardinger K; Brennan DC; Woodward RS; Desai NM; Crippin JS; Gage BF; Schnitzler MA
Am J Transplant; 2004 Oct; 4(10):1703-8. PubMed ID: 15367228
[TBL] [Abstract][Full Text] [Related]
6. Economic Evaluation of Extending Medicare Immunosuppressive Drug Coverage for Kidney Transplant Recipients in the Current Era.
Kadatz M; Gill JS; Gill J; Formica RN; Klarenbach S
J Am Soc Nephrol; 2020 Jan; 31(1):218-228. PubMed ID: 31704739
[TBL] [Abstract][Full Text] [Related]
7. Cost of lifetime immunosuppression coverage for kidney transplant recipients.
Page TF; Woodward RS
Health Care Financ Rev; 2008; 30(2):95-104. PubMed ID: 19361119
[TBL] [Abstract][Full Text] [Related]
8. Future of Medicare immunosuppressive drug coverage for kidney transplant recipients in the United States.
Tanriover B; Stone PW; Mohan S; Cohen DJ; Gaston RS
Clin J Am Soc Nephrol; 2013 Jul; 8(7):1258-66. PubMed ID: 23559679
[TBL] [Abstract][Full Text] [Related]
9. Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.
Machnicki G; Ricci JF; Brennan DC; Schnitzler MA
Pharmacoeconomics; 2008; 26(11):951-67. PubMed ID: 18850764
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Antibody-Based Induction Therapy in Deceased Donor Kidney Transplantation in the United States.
Gharibi Z; Ayvaci MUS; Hahsler M; Giacoma T; Gaston RS; Tanriover B
Transplantation; 2017 Jun; 101(6):1234-1241. PubMed ID: 27379555
[TBL] [Abstract][Full Text] [Related]
11. Labor supply responses to government subsidized health insurance: evidence from kidney transplant patients.
Page TF
Int J Health Care Finance Econ; 2011 Jun; 11(2):133-44. PubMed ID: 21567166
[TBL] [Abstract][Full Text] [Related]
12. Racial differences and income disparities are associated with poor outcomes in kidney transplant recipients with lupus nephritis.
Nee R; Jindal RM; Little D; Ramsey-Goldman R; Agodoa L; Hurst FP; Abbott KC
Transplantation; 2013 Jun; 95(12):1471-8. PubMed ID: 23680929
[TBL] [Abstract][Full Text] [Related]
13. Medicare immunosuppressant coverage and access to kidney transplantation: a retrospective national cohort study.
Grubbs V; Plantinga LC; Vittinghoff E; O'Hare AM; Dudley RA
BMC Health Serv Res; 2012 Aug; 12():254. PubMed ID: 22894737
[TBL] [Abstract][Full Text] [Related]
14. The financial impact of immunosuppressant expenses on new kidney transplant recipients.
Gordon EJ; Prohaska TR; Sehgal AR
Clin Transplant; 2008; 22(6):738-48. PubMed ID: 18673373
[TBL] [Abstract][Full Text] [Related]
15. An (ongoing) shortsighted view on transplant coverage policy.
Zumoff R
Nephrol News Issues; 2012 Mar; 26(3):8, 10. PubMed ID: 22479970
[No Abstract] [Full Text] [Related]
16. Transplant outcomes and economic costs associated with patient noncompliance to immunosuppression.
Pinsky BW; Takemoto SK; Lentine KL; Burroughs TE; Schnitzler MA; Salvalaggio PR
Am J Transplant; 2009 Nov; 9(11):2597-606. PubMed ID: 19843035
[TBL] [Abstract][Full Text] [Related]
17. Effects of antibody induction on transplant outcomes in human leukocyte antigen zero-mismatch deceased donor kidney recipients.
Kuo HT; Huang E; Emami S; Pham PT; Wilkinson AH; Danovitch GM; Bunnapradist S
Transplantation; 2012 Mar; 93(5):493-502. PubMed ID: 22306574
[TBL] [Abstract][Full Text] [Related]
18. Kidney transplantation in the US: an analysis of the OPTN/UNOS registry.
Freitas MC
Clin Transpl; 2011; ():1-16. PubMed ID: 22755397
[TBL] [Abstract][Full Text] [Related]
19. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia.
Neff RT; Jindal RM; Yoo DY; Hurst FP; Agodoa LY; Abbott KC
Transplantation; 2009 Jul; 88(1):135-41. PubMed ID: 19584693
[TBL] [Abstract][Full Text] [Related]
20. Significant racial differences in the key factors associated with early graft loss in kidney transplant recipients.
Taber DJ; Douglass K; Srinivas T; McGillicuddy JW; Bratton CF; Chavin KD; Baliga PK; Egede LE
Am J Nephrol; 2014; 40(1):19-28. PubMed ID: 24969370
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
